Jeil Pharmaceutical Co Ltd Asset Resilience Ratio
Jeil Pharmaceutical Co Ltd asset resilience ratio. Jeil Pharmaceutical Co Ltd (271980) has an Asset Resilience Ratio of 1.69% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 271980 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Jeil Pharmaceutical Co Ltd (2018–2025)
Asset resilience ratio of Jeil Pharmaceutical Co Ltd from 2018 to 2025. This chart shows how Jeil Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read Jeil Pharmaceutical Co Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Jeil Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Jeil Pharmaceutical Co Ltd's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩8.87 Billion | 1.69% |
| Total Liquid Assets | ₩8.87 Billion | 1.69% |
Asset Resilience Insights
- Limited Liquidity: Jeil Pharmaceutical Co Ltd maintains only 1.69% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Jeil Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Jeil Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Jeil Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2018–2025)
Jeil Pharmaceutical Co Ltd asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for Jeil Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.95% | ₩9.96 Billion ≈ $6.75 Million |
₩510.57 Billion ≈ $346.01 Million |
+1.19pp |
| 2024-12-31 | 0.76% | ₩3.98 Billion ≈ $2.70 Million |
₩525.70 Billion ≈ $356.26 Million |
+0.21pp |
| 2023-12-31 | 0.55% | ₩2.67 Billion ≈ $1.81 Million |
₩487.33 Billion ≈ $330.25 Million |
+0.52pp |
| 2022-12-31 | 0.03% | ₩142.46 Million ≈ $96.54K |
₩456.89 Billion ≈ $309.63 Million |
-0.45pp |
| 2021-12-31 | 0.48% | ₩2.04 Billion ≈ $1.38 Million |
₩426.49 Billion ≈ $289.02 Million |
-0.18pp |
| 2020-12-31 | 0.66% | ₩2.69 Billion ≈ $1.83 Million |
₩409.66 Billion ≈ $277.62 Million |
+0.66pp |
| 2019-12-31 | 0.00% | ₩4.76 Million ≈ $3.23K |
₩401.59 Billion ≈ $272.15 Million |
-0.09pp |
| 2018-12-31 | 0.09% | ₩350.00 Million ≈ $237.19K |
₩402.90 Billion ≈ $273.04 Million |
-- |
About Jeil Pharmaceutical Co Ltd
Jeil Pharmaceutical Co.,Ltd develops and supplies pharmaceutical products primarily in South Korea and internationally. It provides products in the areas of antibiotic, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamine. The company exports its products. Jeil Pharmaceutical Co.,Ltd was founded in 1959 and is headquartered in Seoul, So… Read more